More here:
Pacific Biosciences Grants Equity Incentive Award to New Employee
Author Archives: Fredricko
Sorrento Announces Positive Preliminary Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
Immunicum AB (publ) Plans to Expand its Research and Process Development Facilities in Leiden, the Netherlands
Tiziana Life Sciences plc ("Tiziana" or the "Company") – Tiziana Files Registration Statement on Form F-3 with U.S. Securities and…
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136)…
Acasti Pharma Provides Update on Recent Financing Activities
See the article here:
Acasti Pharma Provides Update on Recent Financing Activities
Pluristem Announces Uplisting to the Nasdaq Global Market®
Read this article:
Pluristem Announces Uplisting to the Nasdaq Global Market®
VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients
Go here to see the original:
VBL Therapeutics Treats First Patient in Phase 2 Randomized Controlled Study of VB-201 in COVID-19 Patients
European Medicines Agency Accepts GBT’s Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in…
Mydecine Innovations Group Files Application to list to the NASDAQ
Vaxil Provides Update on USAMRIID, Oral Experiment and Other General Business Matters
PolyPid to Report Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights on February 10, 2021
electroCore, Inc. Announces Inclusion of gammaCore Sapphire™ in new NHS England and NHS Improvement MedTech Funding Mandate Policy 2021/22
Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study
Auron Therapeutics Closes $12.75 Million Seed Financing to Develop Differentiation Therapies for Treatment of Cancers
Vaxart Announces Publication of a Peer-reviewed Journal Article Showing the Potential Clinical and Economic Value of a Norovirus Vaccine
Motus GI Announces Warrant Exercise Agreement Resulting in Expected Gross Proceeds to the Company of up to $11 Million
SetPoint Medical Raises $64M in Preferred Stock Financing to Support Pivotal Trial for its Novel Bioelectronic Platform
Zealand Pharma announces directed issue and private placement corresponding to approx. 10% of existing share capital
Intercept Company Statement on Analyst Note
Excerpt from:
Intercept Company Statement on Analyst Note